Thurston Springer Miller Herd & Titak Inc. Buys 2,914 Shares of Stryker Co. (NYSE:SYK)

Thurston Springer Miller Herd & Titak Inc. lifted its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 50.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,733 shares of the medical technology company's stock after purchasing an additional 2,914 shares during the period. Stryker accounts for 0.6% of Thurston Springer Miller Herd & Titak Inc.'s portfolio, making the stock its 29th largest holding. Thurston Springer Miller Herd & Titak Inc.'s holdings in Stryker were worth $3,145,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of SYK. Park Avenue Securities LLC lifted its holdings in Stryker by 25.3% during the 4th quarter. Park Avenue Securities LLC now owns 10,613 shares of the medical technology company's stock valued at $3,821,000 after purchasing an additional 2,142 shares during the last quarter. Kathmere Capital Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $291,000. Board of the Pension Protection Fund bought a new stake in shares of Stryker during the 4th quarter worth about $144,000. Allen Mooney & Barnes Investment Advisors LLC grew its stake in Stryker by 5.6% in the 4th quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 1,621 shares of the medical technology company's stock valued at $584,000 after buying an additional 86 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in Stryker by 3.2% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 4,204 shares of the medical technology company's stock valued at $1,513,000 after acquiring an additional 129 shares during the period. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SYK. Wells Fargo & Company boosted their price objective on Stryker from $405.00 to $427.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. UBS Group upped their price objective on Stryker from $366.00 to $370.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. Truist Financial boosted their target price on shares of Stryker from $380.00 to $409.00 and gave the company a "hold" rating in a research report on Wednesday, December 18th. Citigroup raised their price target on shares of Stryker from $411.00 to $450.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $442.00 price objective on shares of Stryker in a report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $405.80.

Stryker Price Performance

NYSE SYK traded up $5.29 during trading on Wednesday, hitting $368.09. 1,529,215 shares of the company's stock were exchanged, compared to its average volume of 1,313,268. The stock's 50 day moving average price is $375.13 and its two-hundred day moving average price is $358.25. Stryker Co. has a fifty-two week low of $307.23 and a fifty-two week high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $140.32 billion, a PE ratio of 39.45, a P/E/G ratio of 2.82 and a beta of 0.95.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion during the quarter, compared to analysts' expectations of $5.37 billion. During the same period in the prior year, the company earned $2.46 EPS. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. Research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is an increase from Stryker's previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. Stryker's dividend payout ratio (DPR) is 36.01%.

Insider Buying and Selling

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.